SHANGHAI, Dec. 17, 2010 /PRNewswire-Asia-FirstCall/ --
China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq:
CHBT) the leading developer, manufacturer and distributor of
probiotics products in China,
today announced that it has expanded its distribution network into
the Pan-Beijing area with the selection of four new distributors to
sell the Company's retail products.
These local distributors will sell the Company's retail
probiotics products through established distribution networks
including malls, supermarkets and functional food stores adding
approximately 30 new points of sale. These agreements represent the
Company's first market entry into the pan-Beijing area.
Mr. Jinan Song, Chairman and CEO
of China-Biotics, commented, "We are very excited about our new
alliances with these distributors as they enable us to enter the
highly desirable pan-Beijing area,
which together with the Hebei and
Shandong provinces and the
municipalities of Beijing and
Tianjin, command among the highest
disposable income levels in China
with rising nutritional food consumption. Although the signing of
these distribution agreements signals the beginning of our
expansion into this new geographic region, we have already started
conducting studies on market potential for other regions within
China."
"Rapidly growing sales of probiotics cultured yogurt products by
dairy companies throughout China
are paving the way for increased awareness of the benefit of
probiotics. We are confident that our retail products will be well
received by the health conscious middleclass consumers in this
region. Our goal remains consistent: building a broader retail and
bulk customer base with regular consumption and recurring revenues
to maximize our long-term shareholder value," Mr. Song
concluded.
About China-Biotics
China-Biotics, Inc. ("China-Biotics" or "the Company"), a
leading manufacturer of biotechnology products and supplements,
engages in the research, development, marketing and distribution of
probiotics dietary supplements in China. Through its wholly owned subsidiaries,
Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering
(Shanghai) Co. Ltd., the Company
develops and produces a proprietary product portfolio. Currently,
its retail products are sold over the counter, mainly through large
distributors, to pharmacies and supermarkets in Shanghai and Jiangsu and Zhejiang provinces. The Company also sells
bulk products to institutional customers such as dairy and animal
feed producers as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial
production in China's largest
probiotics production facility to meet the growing demand in
China. For more information,
please visit http://www.chn-biotics.com.
Safe Harbor Statement
The information in this release contains forward-looking
statements which involve risks and uncertainties, including
statements regarding the Company's capital needs, business strategy
and expectations. Any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements, which may be identified by terminology such as "may,"
"should," "will," "expect," "plan," "intend," "anticipate,"
"believe," "estimate," "predict," "potential," "forecast,"
"project," or "continue," the negative of such terms or other
comparable terminology. Readers should not rely on forward-looking
statements as predictions of future events or results. Any or all
of the Company's forward-looking statements may turn out to be
wrong. They can be affected by inaccurate assumptions, risks and
uncertainties and other factors which could cause actual events or
results to be materially different from those expressed or implied
in the forward-looking statements. In evaluating these statements,
readers should consider various factors, including the risks
described in "Item 1A. Risk Factors" beginning on page 17 and
elsewhere in the Company's 2010 Annual Report on Form 10-K. These
factors may cause the Company's actual results to differ materially
from any forward-looking statement. In addition, new factors emerge
from time to time and it is not possible for the Company to predict
all factors that may cause actual results to differ materially from
those contained in any forward- looking statements. The Company
disclaims any obligation to publicly update any forward-looking
statements to reflect events or circumstances after the date of
this document, except as required by applicable law.
Contact:
|
|
|
|
Travis Cai
|
|
Chief Financial Officer
|
|
China-Biotics, Inc.
|
|
traviscai@chn-biotics.com
|
|
|
|
Shiwei Yin/Dixon Chen
|
|
Grayling
|
|
646-284-9474
|
|
shiwei.yin@grayling.com
|
|
dixon.chen@grayling.com
|
|
|
SOURCE China-Biotics, Inc.